Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1197-1206

  Pitts, Raymond C ^c   Allen, Richard M ^a   Walker, Ellen A ^a   Dykstra, Linda A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZAMIDE; BUPRENORPHINE; CLOCINNAMOX; ETORPHINE; MORPHINE; MU OPIATE RECEPTOR; OPIATE AGONIST; OPIATE ANTAGONIST;

ANTINOCICEPTION; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ELECTRIC SHOCK; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SQUIRREL MONKEY;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANESTHETICS, COMBINED; ANIMALS; ANTIGENS, CD; BUPRENORPHINE; CELL ADHESION MOLECULES; CINNAMATES; ETORPHINE; GLYCOPROTEINS; MALE; MORPHINE; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; SAIMIRI;

EID: 0031809204     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Adams JU, Paronis CA and Holtzman SG (1990) Assessment of relative intrinsic activity of mu opioid analgesics in vivo using β-funaltrexamine. J Pharmacol Exp Ther 255:1027-1032.
2. Barrett JE (1987) Nonpharmacological factors determining the behavioral effects of drugs. In Psychopharmacology: The Third Generation of Progress, ed. by Meltzer HY, pp. 1493-1501, Raven Press; New York.
3. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol 220:141-162.
4. Black JW, Leff P, Shankley NP and Wood J (1985) An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84:561-571.
5. Blasig J, Meyer G, Hollt V, Hengstenberg J, Dum J and Herz A (1979) Noncompetitive nature of the antagonistic mechanism responsible for tolerance development to opiate-induced analgesia. Neuropharmacology 18:473-481.
6. Branch MN (1991) Behavioral pharmacology. In Experimental Analysis of Behavior, Part 2, ed. by Iverson IH and Lattal KA, pp. 21-77, Elsevier, Amsterdam.
7. Burke TF, Woods JH, Lewis JW and Medzihradsky F (1994) Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther 271:715-721.
8. Butelman ER, Lewis JW and Woods JH (1996b) Methoclocinnamox: Agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys. J Pharmacol Exp Ther 279:934-938.
9. Butelman ER, Negus SS, Lewis JW and Woods JH (1996a) Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys. Psychopharmacology 123:320-324.
10. Comer SD, Burke TF, Lewis JW and Woods JH (1991) Clocinnamox: A novel, systemically active, irreversible opioid antagonist. J Pharmacol Exp Ther 262: 1051-1056.
11. Craft RM and Dykstra LA (1990) Differential cross-tolerance to opioids in squirrel monkeys responding under a shock titration schedule. J Pharmacol Exp Ther 252:945-952.
12. DeRossett SE and Holtzman SG (1984) Effects of naloxone, diprenorphine, buprenorphine and etorphine on unpunished and punished food-reinforced responding in the squirrel monkey. J Pharmacol Exp Ther 228:669-675.
13. Dykstra LA (1979) Effects of morphine, pentazocine, and cyclazocine alone and in combination with naloxone on electric shock titration in the squirrel monkey. J Pharmacol Exp Ther 211:722-732.
14. Dykstra LA (1983) Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys. J Pharmacol Exp Ther 226:317-323.
15. Dykstra LA (1985) Effects of buprenorphine on shock titration in squirrel monkeys. J Pharmacol Exp Ther 235:20-25.
16. 2 analysis. In Psychopharmacology Series 4: Transduction Mechanisms of Drug Stimuli, ed. by Colpaert FC and Balster RL, pp. 107-121, Springer-Verlag, Berlin.
17. Dykstra LA, Gmerek DE and Woods JH (1987) Kappa opioid agonists in rhesus monkeys. II. Analysis of the antagonist actions of quadazocine and β-funaltrexamine. J Pharmacol Exp Ther 242:421-427.
18. Dykstra LA and Massie CA (1988) Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey. J Pharmacol Exp Ther 246:813-821.
19. Dykstra LA and McMillan DE (1977) Electric shock titration: Effects of morphine, methadone, pentazocine, nalorphine, naloxone, diazepam and amphetamine. J Pharmacol Exp Ther 202:660-669.
20. Dykstra LA and Negus SS (1995) Behavioral and pharmacological determinants of buprenorphine's effects on schedule-controlled behavior. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid, pp. 49-69, Wiley-Liss, Inc..
21. Furchgott RF (1966) The use of haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In Advances in Drug Research, ed. by Harper H and Simmons A, pp. 21-55, Academic Press, New York.
22. Hoffman HS (1966) The analysis of discriminated avoidance. In Operant Behavior: Areas of Research and Application, ed. by Honig WK, pp. 499-530, Appleton-Century-Crofts, New York.
23. Hughes CE, Picker MJ and Dykstra LA (1995) Tolerance and cross-tolerance to the response rate-decrasing effects of μ opioids in morphine maintained squirrel monkeys. Behav Pharmacol 6:776-784.
24. Jiang Q, Heyman JS, Sheldon RJ, Koslo RJ and Porreca F (1990) Mu antagonist and kappa agonist properties of β-funaltrexamine (β-FNA) in vivo: Long-lasting spinal analgesia in mice. J Pharmacol Exp Ther 252:1006-1011.
25. Martin TJ, Dworkin SI and Smith JE (1995) Alkylation of mu opioid receptors by β-funaltrexamine in vivo: Comparison of the effects on in situ binding and heroin self-administration in rats. J Pharmacol Exp Ther 272:1135-1140.
26. Mjanger E and Yaksh TL (1991) Characteristics of dose-dependent antagonism by β-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. J Pharmacol Exp Ther 258:544-550.
27. Negus SS and Dykstra LA (1988) κ Antagonist properties of buprenorphine in the shock titration procedure. Eur J Pharmacol 156:77-86.
28. Paronis CA and Holtzman SG (1992) Development of tolerance to the analgesic activity of mu agonists after continuous infustion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 262:1-9.
29. Paronis CA and Holtzman SG (1994) Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists. Psychopharmacology 114:601-610.
30. Pitts RC and Dykstra LA (1994) Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys. J Pharmacol Exp Ther 271: 1501-1508.
31. Pitts RC, West JP, Hapke DM, Morgan D, Dykstra LA and Picker MJ (1996) Opioids and positively reinforced behavior. II. Antagonism by β-funaltrexamine. Exp Clin Psychopharmacol 4:389-395.
32. Porreca F, Cowan A, Raffa RB and Tallarida RJ (1982) Estimation in vivo of the receptor constants of morphine in naive and morphine-tolerant rats. Life Sci 31:2355-2358.
33. Richards ML and Sadée W (1985) In vivo opiate receptor binding of oripavines to μ, and sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol 114:343-353.
34. Sadée W, Rosenbaun JS and Herz A (1982) Buprenorphine: Differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223:157-162.
35. Smith JB and McKearney JW (1977) Effects of morphine, methadone, nalorphine and naloxone on responding under schedules of electric shock titration. J Pharmacol Exp Ther 200:508-515.
36. Tallarida RJ and Cowan A (1982) The affinity of morphine for its pharmacologic receptor in vivo. J Pharmacol Exp Ther 222:198-201.
37. Tang AH and Collins RJ (1985) Behavioral effects of a novel opioid analgesic, U-50488, in rats and rhesus monkeys. Psychopharmacology 85:309-314.
38. Walker EA, Zernig G and Woods JH (1995) Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273: 1345-1352.
39. Walker EA, Zernig G and Young AM (1998) In vivo apparent affinity and efficacy estimates for μ opiates in a rat tail-withdrawal assay. Psychopharmacology 136: 15-23.
40. Ward SJ, Portoghese PS and Takemori AE (1982) Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J Pharmacol Exp Ther 220:494-498.
41. Wolfram S (1991) Mathematica: A System for Doing Mathematics by Computer. 2nd ed. Addison-Wesley, Reading.
42. Yaksh TL and Rudy TA (1977) A dose-ratio comparison of the interaction between morphine and cyclazocine with naloxone in rhesus monkeys on the shock titration task. Eur J Pharmacol 46:83-92.
43. Young AM, Kapitsopoulos G and Makhay MM (1991) Tolerance to morphine-like stimulus effects of mu opioid agonists. J Pharmacol Exp Ther 257:795-805.
44. Zernig G, Broadbear J, Lew JW, Brine GA and Woods JH (1995a) Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox. Exp Clin Psychopharmacol 4:323-329.
45. Zernig G, Burke TFLewis JW and Woods JH (1996a) Mechanism of clocinnamox blockade of opioid receptors: Evidence from in vitro and ex vivo binding and behavioral assays. J Pharmacol Exp Ther 279:23-31.
46. Zernig G, Butelman ER, Lewis JW, Walker EA and Woods JH (1994) In vivo determination of mu receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 260:57-65.
47. Zernig G and Issaevitch T (1995) Software for the Calculation of Agonist Efficacy and Apparent in Vivo Affinity by Simultaneous Analysis of Severval Dose-Response Curves. Wolfram Research, Champaign, IL.
48. Zernig G, Issaevitch T, Broadbear J, Burke TF, Lewis JW, Brine GA and Woods JH (1995b) Receptor reserve and affinity of μ opioid agonists in mouse antinociception: Correlation with receptor binding. Life Sci 57:2113-2125.
49. Zernig G, Issaevitch T and Woods JH (1996b) Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: Comparison of different analytical approaches. J Pharmacol Toxicol Methods
50. Zernig G, Lewis JW and Woods JH (1997) Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: Comparison with effects on opioid agonist-media ted antinociception. Psychopharmacology 129:233-242.
51. Zimmerman DM, Leander JD, Reel JK and Hynes MD (1987) Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J Pharmacol Exp Ther 241:374-378.